Marshall Wace North America L.P. acquired a new position in shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 40,416 shares of the biopharmaceutical company’s stock, valued at approximately $242,000. Marshall Wace North America L.P. owned 0.14% of CymaBay Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its stake in CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 140 shares during the period. LVM Capital Management Ltd. MI grew its stake in CymaBay Therapeutics by 100.0% during the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 10,000 shares during the period. Boxer Capital LLC purchased a new stake in CymaBay Therapeutics during the first quarter worth approximately $3,342,000. Renaissance Technologies LLC grew its stake in CymaBay Therapeutics by 97.6% during the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after buying an additional 114,549 shares during the period. Finally, ClariVest Asset Management LLC purchased a new stake in CymaBay Therapeutics during the first quarter worth approximately $105,000. Institutional investors own 25.80% of the company’s stock.

Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) opened at 7.20 on Friday. CymaBay Therapeutics Inc. has a 12-month low of $1.15 and a 12-month high of $8.29. The company has a 50-day moving average of $6.61 and a 200 day moving average of $5.08. The firm’s market capitalization is $315.04 million.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.06). On average, analysts predict that CymaBay Therapeutics Inc. will post ($0.81) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Marshall Wace North America L.P. Takes Position in CymaBay Therapeutics Inc. (CBAY)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/16/marshall-wace-north-america-l-p-takes-position-in-cymabay-therapeutics-inc-cbay.html.

In related news, SVP Charles Mcwherter acquired 5,000 shares of the stock in a transaction dated Thursday, July 20th. The shares were acquired at an average price of $7.43 per share, for a total transaction of $37,150.00. Following the completion of the purchase, the senior vice president now owns 5,100 shares in the company, valued at approximately $37,893. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sujal Shah acquired 10,000 shares of the stock in a transaction dated Thursday, July 20th. The stock was bought at an average price of $7.34 per share, for a total transaction of $73,400.00. Following the purchase, the insider now owns 75,891 shares of the company’s stock, valued at approximately $557,039.94. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 20,000 shares of company stock worth $144,750. Corporate insiders own 15.10% of the company’s stock.

Several equities research analysts have issued reports on the stock. Piper Jaffray Companies reiterated an “overweight” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research note on Tuesday, July 25th. Oppenheimer Holdings, Inc. boosted their target price on shares of CymaBay Therapeutics from $8.00 to $15.00 and gave the stock an “outperform” rating in a research report on Thursday, July 20th. Ifs Securities reissued a “strong-buy” rating on shares of CymaBay Therapeutics in a research report on Monday, July 17th. Zacks Investment Research cut shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Finally, CIBC reissued an “outperform” rating and set a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $12.28.

CymaBay Therapeutics Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc. (NASDAQ:CBAY).

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Stock Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related stocks with our FREE daily email newsletter.